This video is featured in the 2024 ASH Annual Meeting Insights Hub

2024 ASH Annual Meeting Insights Hub
Avatar

ASH 2024 Insights: Updated Ph3 MANIFEST-2 Results - Pelabresib + Ruxolitinib for JAK Inhibitor–Naïve Patients With MF

By 2024 ASH Annual Meeting Insights Hub FEATURING John Mascarenhas
By 2024 ASH Annual Meeting Insights Hub FEATURING John Mascarenhas
31 views
December 27, 2024
Comments 0
Login to view comments. Click here to Login

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

2024 ASH Annual Meeting Insights Hub: MDS & MPN Videos

11:06

New

ASH 2024 Insights: Ph3 BOREAS Study - Navtemadlin vs. Best Available…

2024 ASH Annual Meeting Insights Hub

J. Mascarenhas

04:51

New

ASH 2024 Summary: Survival Outcomes in Patients With MF & New or Wor…

2024 ASH Annual Meeting Insights Hub

A. Kuykendall

27 views
08:20

New

ASH 2024 Insights: Ven + HMA vs. HMA Alone in TP53m HR-MDS - Real-Wo…

2024 ASH Annual Meeting Insights Hub

T. Badar

22 views
View All

Related Videos

Total Health

West Oncology Conference

Sat, Feb 8, 2025
24:08

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Indy Hematology Review

A. Tefferi

1.5K views
24:35

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Indy Hematology Review

A. Tefferi

1.3K views
14:01

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

473 views
25:44

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

283 views
19:57

New

ASH 2024 Summary: MPN Highlights and Clinical Implications

2024 ASH Annual Meeting Insights Hub

D. Tremblay

128 views
07:44
Incyte

Optimizing the Management of Patients with Polycythemia Vera (PV)

Feat. P. Bose, R. Rampal
10:01

New

ASH 2024 Summary: Pegylated Interferon in MPN - The Who, Why, and How

2024 ASH Annual Meeting Insights Hub

J. Kiladjian

91 views
21:38

Allele Burden in MPN: Practical Considerations

16th International Congress on Myeloproliferative Neoplasms

R. Rampal

135 views
15:43
Incyte

Importance of Early Management of Patients with Myelofibrosis (MF)

Feat. P. Bose, R. Rampal
16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison
20:15

Current and Future Treatment Landscape of Myelofibrosis

XV Eurasian Hematology-Oncology Congress - EHOC 2024

R. Komrokji

164 views
20:54

New

Novel Agents for MPNs in 2024

16th International Congress on Myeloproliferative Neoplasms

N. Pemmaraju

102 views
16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison
06:18

SIMPLIFY-2 Trial: Momelotinib Vs. Continued Ruxolitinib or Best Avai…

Cleveland Clinic Taussig Cancer Institute

A. Gerds

301 views
18:07

New

Selection of JAK1/2 Inhibitors for Primary Myelofibrosis

16th International Congress on Myeloproliferative Neoplasms

A. Gerds

78 views
35:48

Experts Discuss How They Choose 2L Therapy in MF

MyCancerHaven

R. Vij, P. Bose

163 views
17:23

Management of MF After Ruxolitinib Failure

Vanderbilt University Medical Center (VUMC)

A. Kishtagari

195 views
08:06

Current Management of Accelerated/Blast-Phase MPNs

UChicago Medicine

A. Patel

76 views
30:03

Experts Discuss Their Current Approach to Treating MF

MyCancerHaven

R. Vij, A. Yacoub

126 views
24:48

2024 Updates on Myelofibrosis and Systemic Mastocytosis

Indy Hematology Review

R. Rampal

333 views
AUTOPLAY